Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 21Phase 3 12Phase 1/2 8Phase NA 3Phase EARLY_PHASE1 3Phase 2/3 2Phase 4 1

Status

Completed 4Recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 5Colorectal Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Lymphoma 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Melanoma 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Glioblastoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Mouth Neoplasms 2Leukemia 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hyperthermia 2

Interventions

liposomal doxorubicin 2Doxorubicin 2olaparib 1cediranib 1atezolizumab 1Topotecan 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Active not recruiting × Fallopian Tube Neoplasms × Clear all
NCT02839707 2026-05-04

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
444 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡